Improved outcomes in nephrotic syndrome
Gerald B. Appel, MD
Director of Clinical Nephrology and Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons, New York, NY
Address: Gerald B. Appel, MD, Presbyterian Hospital, 622 West 168th Street, Room 4124, New York, NY 10032
The author indicates that he has been a speaker and a consultant for and has received research support from the Merck, Pfizer, AstraZeneca, Bristol-Myers Squib, Aspreva, Novartis, Roche, and Genentech corporations.
Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic Foundation. They are approved by the author but are not peer-reviewed.
ABSTRACTNephrotic syndrome can now be treated effectively in most cases. All patients should be treated with a low-salt diet, diuretics to reduce edema, and statins to normalize serum lipid concentrations. Patients with nephrotic syndrome are prone to deep vein thrombophlebitis, renal vein thrombosis, and pulmonary emboli. Depending on the condition, additional treatment may include corticosteroids, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), cyclosporine, cytotoxic agents, or mycophenolate.